FY2025 Earnings Estimate for HIMS Issued By Leerink Partnrs

Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) - Equities research analysts at Leerink Partnrs lifted their FY2025 EPS estimates for shares of Hims & Hers Health in a research report issued to clients and investors on Tuesday, November 5th. Leerink Partnrs analyst M. Cherny now forecasts that the company will post earnings per share of $0.49 for the year, up from their prior estimate of $0.39. The consensus estimate for Hims & Hers Health's current full-year earnings is $0.22 per share.

Several other brokerages have also commented on HIMS. TD Cowen boosted their price target on shares of Hims & Hers Health from $15.00 to $25.00 and gave the stock a "buy" rating in a report on Thursday, July 11th. Canaccord Genuity Group boosted their price target on shares of Hims & Hers Health from $24.00 to $28.00 and gave the company a "buy" rating in a research report on Tuesday. Bank of America upped their target price on shares of Hims & Hers Health from $23.00 to $25.00 and gave the company a "buy" rating in a research report on Monday, October 21st. Needham & Company LLC started coverage on shares of Hims & Hers Health in a research note on Thursday, August 22nd. They set a "buy" rating and a $24.00 price target on the stock. Finally, Imperial Capital cut shares of Hims & Hers Health from an "outperform" rating to an "in-line" rating in a research report on Friday, August 9th. Eight investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $21.00.

Hims & Hers Health Price Performance

NYSE HIMS traded up $0.39 on Thursday, hitting $23.81. The company had a trading volume of 9,152,176 shares, compared to its average volume of 8,621,208. The company has a market capitalization of $5.11 billion, a PE ratio of 54.80 and a beta of 1.06. The company's fifty day moving average price is $18.40 and its 200-day moving average price is $18.29. Hims & Hers Health has a 12-month low of $6.58 and a 12-month high of $25.74.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its earnings results on Monday, November 4th. The company reported $0.32 earnings per share for the quarter, beating the consensus estimate of $0.06 by $0.26. The firm had revenue of $401.56 million during the quarter, compared to analyst estimates of $382.20 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 11.67%. The business's quarterly revenue was up 77.1% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.04) EPS.

Institutional Investors Weigh In On Hims & Hers Health

A number of institutional investors and hedge funds have recently modified their holdings of the company. Royce & Associates LP lifted its stake in Hims & Hers Health by 17.0% in the 3rd quarter. Royce & Associates LP now owns 341,000 shares of the company's stock valued at $6,281,000 after buying an additional 49,500 shares in the last quarter. Victory Capital Management Inc. raised its position in shares of Hims & Hers Health by 164.9% in the 3rd quarter. Victory Capital Management Inc. now owns 51,577 shares of the company's stock worth $950,000 after buying an additional 32,108 shares during the period. WealthPlan Investment Management LLC purchased a new position in shares of Hims & Hers Health in the 3rd quarter worth $1,042,000. Versor Investments LP purchased a new position in shares of Hims & Hers Health in the 3rd quarter worth $634,000. Finally, Los Angeles Capital Management LLC increased its holdings in Hims & Hers Health by 40.8% in the 3rd quarter. Los Angeles Capital Management LLC now owns 40,353 shares of the company's stock valued at $743,000 after purchasing an additional 11,686 shares in the last quarter. Institutional investors and hedge funds own 63.52% of the company's stock.

Insider Activity

In other Hims & Hers Health news, insider Soleil Boughton sold 2,339 shares of the company's stock in a transaction that occurred on Tuesday, October 29th. The stock was sold at an average price of $23.16, for a total transaction of $54,171.24. Following the completion of the sale, the insider now directly owns 169,935 shares of the company's stock, valued at $3,935,694.60. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Hims & Hers Health news, Director Christiane Pendarvis sold 7,000 shares of the business's stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $15.15, for a total transaction of $106,050.00. Following the transaction, the director now owns 23,917 shares in the company, valued at approximately $362,342.55. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Soleil Boughton sold 2,339 shares of the company's stock in a transaction that occurred on Tuesday, October 29th. The stock was sold at an average price of $23.16, for a total value of $54,171.24. Following the completion of the sale, the insider now owns 169,935 shares in the company, valued at approximately $3,935,694.60. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 650,659 shares of company stock valued at $11,712,198. Insiders own 17.71% of the company's stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.